硝苯地平联合卡托普利与厄贝沙坦氢氯噻嗪治疗原发性高血压的疗效比较被引量：15

导出

摘要目的比较厄贝沙垃氢氯噻嗪与硝苯地平联用卡托普利对原发性高血压降压的疗效。方法选择原发性高血压病患者80例,随机分为A、B两组,每组各40例。A组服用厄贝沙坦氢氯噻嗪150 mg+12.5 mg;对反应不足者,可睡前加服1片,且此剂量为每日最大服用剂量。B组每次口服硝苯地平10 mg加卡托普利25 mg.每日3次。连续口服3 d后,根据血压情况增减剂量。观察期为4周。结果与治疗前相比,A、B组病人收缩压和舒张压均降低(P<0.05),A、B两组之间收缩压和舒张压在治疗前后均无显著差别(P<0.05)。A、B两组有效率分别为82.6%和78.3%。不良反应分别为12.5%和15.0%,两组间无显著差异(P<0.05)。结论国产厄贝沙坦氢氯噻嗪能有效治疗老年原发性高血压,安全有效。

作者陶智虎潘泉

机构地区安徽当涂县人民医院内科

出处《中国临床保健杂志》 CAS 2011年第2期190-192,共3页 Chinese Journal of Clinical Healthcare

关键词高血压氢氯噻嗪硝苯地平卡托普利

分类号 R544.11 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献11

1卫生部心血管病防治研究中心.中国心血管病报告2006[M].北京:中国大百科全书出版社,2008.
2姜红,柯元南,Lodoz临床协作组.比索洛尔／氢氯噻嗪复方片治疗中国轻中度原发性高血压的临床疗效和安全性研究[J].中华心血管病杂志,2006,34(7):605-608. 被引量：34
3孙宁玲,荆珊,陈捷.厄贝沙坦/氢氯噻嗪复方片剂治疗中国高血压病患者的达标率分析[J].中华心血管病杂志,2005,33(7):618-621. 被引量：106
4Lewington S,Clarke R,Qizilbash N,et al.Age-specific relevance of usual blood pressure to vascular mortality:a meta-analasis of individual data for one million adults in 61 prospective studies[J].Lancet,2002,360(9349):1903-1913.
5Hansson L,Zanchetti A,Carruthers SG,et al.Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension:principal results of the Hypertension Optimal Treatment(HOT)randomized trial[J].Lancet,1998,351(9118):1755-1762.
6Asmar R.Targeting effective blood pressure control with angiotension receptor blockes[J].Int J Clin Pract,2006,60(30):315-320.
7Neutel JM,Littlejohn TV,Chrysant SC,et al.Telmisartan/hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in managing patients with mild to moderate hypertension[J].Hypertens Res,2005,28(7):555-63.
8张小玲,陈坷,叶青,范西真,严激.厄贝沙坦/氢氯噻嗪复方片剂治疗轻中度高血压的疗效观察[J].中国临床保健杂志,2008,11(3):292-293. 被引量：17
9尚晓斌,曾知恒.厄贝沙坦/氢氯噻嗪复方片剂(安博诺)治疗高血压的理论与实践[J].内科,2006,1(2):158-162. 被引量：2
10Malion JM,Carretta R,Trenkwalder P,et al.Valsartanhydrochlorothiazide is effective in hypertensive patients inadequstely controlled by valsartan monotherapy[J].Blood press Suppl,2003,Suppl 1:36.

二级参考文献18

1刘力生.2004年中国高血压防治指南(实用本)[J].中华心血管病杂志,2004,32(12):1060-1064. 被引量：2611
2沈潞华.利尿剂在高血压治疗中的作用[J].中国临床医生杂志,2005,33(7):14-15. 被引量：1
3孙宁玲,荆珊,陈捷.厄贝沙坦/氢氯噻嗪复方片剂治疗中国高血压病患者的达标率分析[J].中华心血管病杂志,2005,33(7):618-621. 被引量：106
4Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension, 2003,42:239-246.
5Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet,2000,29;356:366-372.
6Howe P, Phillips P, Saini R, et al.The antihypertensive efficacy of the combination of irbesartan and hydrochlorothiazide assessed by 24-hour ambulatory blood pressure monitoring. Irbesartan Multicenter Study Group. Clin Exp Hypertens. 1999,21:1373-1396.
7中国高血压防治指南起草委员会.1999中国高血压防治指南[J].高血压杂志,2000,8:94-112.
8European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens,2003,21:1011-1053.
9Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.Lancet. 1998,351:1755-1762.
10European society of hypertension-European society of cardiology guidelines committee.2003 European society of hypertension-European society of cardiology guidelines for the management of arterial hypertension[J].J Hypertens,2003,21:1011-1053.